CLAIMS

What is claimed is:

1. A composition comprising ~~a 5-HT$_{2A}$ antagonist, a norepinephrine-dopamine reuptake inhibitor~~trazodone in a dosage range of 25 – 450 mg and bupropion, and a pharmaceutically acceptable carrier.

~~2. A composition, comprising trazodone in a dosage range of 25-450 mg and bupropion.~~

~~3~~2. The composition of claim ~~2~~1, comprising trazodone in a dosage range of 25-450 mg and bupropion in a dosage range of 200-450 mg.

~~4~~3. A method of making a composition comprising combining ~~a 5-HT$_{2A}$ antagonist, a norepinephrine-dopamine reuptake inhibitor~~ trazodone in a dosage range of 25 – 450 mg and bupropion, and a pharmaceutically acceptable carrier.

~~5. The method of claim 4, comprising combining bupropion, trazodone, and a pharmaceutically acceptable carrier.~~

~~6~~4. A ~~method of treating sexual disorder (SD) in a subject comprising administering to the subject a~~ composition according to claim ~~2~~1, for use in treatment of sexual disorder (SD) in a subject.

~~7~~5. The ~~method~~ composition of claim ~~6~~4, wherein the SD is female orgasm disorder (FOD).

~~8~~6. The ~~method~~ composition of claim ~~6~~4, wherein the SD is female sexual arousal disorder (FSAD).

~~9~~7. The ~~method~~ composition of claim ~~6~~4, wherein the SD is sexual pain dysfunction.

~~10~~8. A ~~method of treating a diagnostic and statistical manual of mental disorders (DSM-IV) disorder in a subject comprising administering to the subject a~~ composition according to claim ~~2~~1, for use in treatment of a diagnostic and statistical manual of mental disorders (DSM-IV) disorder in a subject.

~~11~~9. A ~~method of treating erectile dysfunction (ED) in a subject comprising administering to the subject a~~ composition according to claim 1, for use in treatment of erectile dysfunction (ED) in a subject.

~~12~~10. The ~~method~~ composition of any one of claims ~~6, 10 or 11~~4, 8, or 9, wherein the composition is administered orally.

~~13~~11. The ~~method~~ composition of any one of claims ~~6, 10 or 11~~4, 8, or 9, wherein the composition is administered topically.

~~14~~12. The ~~method~~ composition of any one of claims ~~6, 10 or 11~~4, 8, or 9, wherein the subject is diagnosed and being treated for depression.

~~15~~13. The ~~method~~ composition of any one of claims ~~6, 10 or 11~~4, 8, or 9, wherein the subject is not undergoing treatment for depression.

~~16~~14. The ~~method~~ composition of any one of claims ~~6, 10 or 11~~4, 8, or 9, wherein the subject is concurrently prescribed an additional therapeutic agent.

~~17~~15. The ~~method~~ composition of any one of claims ~~6, 10 or 11~~4, 8, or 9, wherein the subject is concurrently not prescribed an additional therapeutic agent.

~~18~~16. An extended release composition comprising ~~a 5-HT$_{2A}$ antagonist, a norepinephrine-dopamine reuptake inhibitor~~ trazodone in a dosage range of 25 – 450 mg and bupropion, and a pharmaceutically acceptable carrier.

~~19~~17. The composition of claim ~~2~~1, wherein the composition is suitable for oral administration.

~~20~~18. The composition of claim ~~2~~1, wherein the composition is suitable for topical administration.

~~21~~19. A kit comprising a composition according to claim ~~2~~ 1 and a label providing instructions for administration of the composition to a subject for treating or ameliorating SD or symptoms thereof in the subject.

~~22~~20. A single dosage composition comprising ~~a 5-HT$_{2A}$ antagonist, a norepinephrine-dopamine reuptake inhibitor~~ trazodone in a dosage range of 25 – 450 mg and bupropion, and a pharmaceutically acceptable carrier.

~~23~~21. A ~~method of treating sexual disorder (SD) in a subject comprising administering to the subject a 5-HT$_{2A}$ antagonist and a norepinephrine-dopamine reuptake inhibitor~~composition comprising trazodone in a dosage range of 25 – 450 mg and bupropion, and a pharmaceutically acceptable carrier for use in treatment of sexual disorder (SD) in a subject.

.

~~24~~22. A ~~method of treating a diagnostic and statistical manual of mental disorders (DSM-IV) disorder in a subject comprising administering to the subject a 5-HT$_{2A}$ antagonist and a norepinephrine-dopamine reuptake inhibitor~~ composition comprising trazodone in a dosage range of 25 – 450 mg and bupropion, and a pharmaceutically acceptable carrier for use in treatment of a diagnostic and statistical manual of mental disorders (DSM-IV) disorder in a subject.

~~25~~23. A ~~method of treating erectile dysfunction (ED) in a subject comprising administering to the subject a 5-HT$_{2A}$ antagonist and a norepinephrine-dopamine reuptake inhibitor~~composition comprising trazodone in a dosage range of 25 – 450 mg and bupropion, and a pharmaceutically acceptable carrier for use in treatment of erectile dysfunction (ED) in a subject.

~~26~~24. A method of making a composition comprising combining a 5-HT$_{1A}$ receptor agonist and a pharmaceutically acceptable carrier such that the composition comprises a range of 25-450 of a 5-HT$_{1A}$ receptor agonist and a norepinephrine-dopamine reuptake inhibitor.

~~27~~25. A method of making a composition comprising combining a 5-HT$_{2A}$ antagonist and a pharmaceutically acceptable carrier such that the composition comprises a range of 25-450 mg of a 5-HT$_{2A}$ antagonist and a norepinephrine-dopamine reuptake inhibitor.

26. Bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, each in a prophylactically effective amount for use in combination therapy for preventing and/or treating a sexual disorder in a subject, wherein the combination therapy is more effective in the prevention and/or treatment of the sexual disorder than when either the bupropion or the trazodone is used alone in the same amount as used in the combination therapy to prevent and/or treat the sexual disorder.

27. Bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, each in a prophylactically effective amount for use in combination therapy for preventing and/or treating a sexual disorder in a subject, wherein the combination therapy causes reduced toxicity than when the trazodone is used alone in the same amount as used in the combination therapy to prevent and/or treat the sexual disorder.

28. Bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, each in a prophylactically effective amount for use as a medicament for preventing and/or treating a sexual disorder in a subject, wherein the

medicament is more effective in the prevention and/or treatment of the sexual disorder than when either the bupropion or the trazodone is used alone in the same amount as used in the medicament to prevent and/or treat the sexual disorder.

29. Bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, each in a prophylactically effective amount for use as a medicament for preventing and/or treating a sexual disorder in a subject, wherein the combination causes reduced toxicity than when the trazodone is used alone in the same amount as used in the medicament to prevent and/or treat the sexual disorder.

30. Bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, each in an effective amount for use in combination therapy for the treatment of a sexual disorder in a subject, wherein the combination therapy is more effective in the treatment of the sexual disorder than when either the bupropion or the trazodone is used alone in the same amount as used in the combination therapy to treat a sexual disorder.

31. Bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, each in an effective amount for use in combination therapy for the treatment of a sexual disorder in a subject, wherein the combination therapy causes reduced toxicity than when the trazodone is used alone in the same amount as used in the combination therapy to treat the sexual disorder.

32. Bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, each in an effective amount for use as a medicament for the treatment of a sexual disorder in a subject, wherein the medicament is more effective in the treatment of the sexual disorder than when either the bupropion or the trazodone is used alone in the same amount as used in the medicament to treat the sexual disorder.

33. Bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, each in an effective amount for use as a medicament for the treatment of a sexual disorder in a subject, wherein the medicament causes reduced toxicity than when the trazodone is used alone in the same amount as used in the medicament to treat the sexual disorder.

34. The use of bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof for the manufacture of a medicament for the prevention and/or treatment of a sexual disorder in a subject, wherein each is in a prophylactically effective amount in the medicament, and wherein the medicament is more effective in the prevention and/or the treatment of the sexual disorder than when either the bupropion or the trazodone is used alone in the same amount as used in the medicament to prevent and/or treat the sexual disorder.

35. The use of bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, for the manufacture of a medicament for the prevention and/or the treatment of a sexual disorder in a subject, wherein each is in a prophylactically effective amount in the medicament, and wherein the medicament causes reduced toxicity than when the trazodone is used alone in the same amount as used in the medicament to prevent and/or treat the sexual disorder.

36. The use of bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof for the manufacture of a medicament for the treatment of a sexual disorder in a subject, wherein each is in an effective amount in the medicament, and wherein the medicament is more effective in the treatment of the sexual disorder than when either the bupropion or the trazodone is used alone in the same amount as used in the medicament to treat the sexual disorder.

37. The use of bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, for the manufacture of a medicament for the treatment of a sexual disorder in a subject, wherein each is in an effective amount in the medicament, and wherein the medicament causes reduced toxicity than when the trazodone is used alone in the same amount as used in the medicament to treat the sexual disorder.

38. The claims of 26-37, wherein the sexual disorder is female sexual dysfunction.

39. The claim of 38, wherein the female sexual dysfunction concerns sexual desire, arousal, anorgasmia, and/or pain.

40. The claim of 38, wherein the female sexual dysfunction is hypoactive sexual desire disorder (HSDD).

41. The claim of 38, wherein the female sexual dysfunction is female sexual interest arousal disorder.

42. The claim of 38, wherein the female sexual dysfunction is female orgasmic disorder (FOD).

43. The claim of 38, wherein the female sexual dysfunction is female sexual arousal disorder (FSAD).

44. The claims of 38, wherein the female sexual dysfunction is sexual pain disorder.

45. The claims of 38, wherein the female sexual dysfunction is described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) .

46. The claims of 26-37, wherein the sexual dysfunction is a male sexual disorder (MSD).

47. The claim of 46, wherein the male dysfunction is erectile dysfunction (ED).

48. The claims of 26-47, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage range of 25-450 mg.

49. The claims of 26-47, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage range of 200-450 mg.

50. The claims of 26-47, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage range of 225-300 mg.

51. The claims of 26-47, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage range of 200-275 mg.

52. The claims of 26-47, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage range of 100-450 mg.

53. The claims of 26-47, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage range of 100-275 mg.

54. The claims of 26-47, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage range of 25-275 mg.

55. The claims of 26-47, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage range of XX-YY mg, wherein XX is an integer between 5 and 400 and YY is an integer between 50 and 450.

56. The claims of 26-47, wherein the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage range of 25-450 mg.

57. The claims of 26-47, wherein the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage range of 75-150 mg.

58. The claims of 26-47, wherein the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage range of 50-100 mg.

59. The claims of 26-47, wherein the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage range of XX-YY mg, wherein XX is an integer between 25 and 400 andYY is an integer between 50 and 450.

60. The claims of 26-47, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage range of 50-450 mg and the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage range of 25-450 mg.

61. The claims of 26-47, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage range of 200-450 mg and the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage range of 25-450 mg.

62. The claims of 26-47, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage range of 100-300 mg administered once a day and comprising trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage range of 75-150 mg administered once a day.

63. The claims of 26-47, wherein bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage range of 225-300 mg administered once a day and comprising trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage range of 75-150 mg administered once a day.

64. The claims of 26-47, wherein bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage range of 100-275 mg administered once a day and comprising trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage range of 50-100 mg administered once a day.

65. The claims of 26-47, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage range of 200-275 mg administered once a day and the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage range of 50-100 mg administered once a day.

66. The claims of 26-47, wherein the trazadone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage amount of 25 mg administered twice daily and the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage amount of 150 mg administered in the morning and a dosage amount of 100 mg administered once a day at night.

67. The claims of 26-47, wherein the trazadone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage amount of 50 mg administered three times a day and the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a dosage amount of 75 mg administered three times a day.

68. The claims of 26-47, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, are in a ratio of 6 to 1.

69. The claims of 26-47, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, are in a ratio of 5 to 1.

70. The claims of 26-47, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, are in a ratio of 4 to 1.

71. The claims of 26-39, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, are in a ratio of 3 to 1.

72. The claims of 26-39, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, are in a ratio of 2 to 1.

73. The claims of 26-39, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, are in a ratio of 3 to 2.

74. The claims of 26-39, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, are in a ratio of 4 to 3.

75. The claims of 26-39, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, are in a ratio of 11 to 4.

76. The claims of 26-75, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a sustained release oral dosage form.

77. The claims of 26-75, wherein the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in an extended release oral dosage form.

78. The claims of 26-75, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a sustained release oral dosage form and the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in an extended release oral dosage form.

79. The claims of 26-78, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is administered once a day and the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is administered once a day.

80. The claims of 26-78, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is administered once a day and the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is administered once a day at night.

81. The claims of 26-78, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is administered twice daily and the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is administered once a day.

82. The claims of 26-78, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is administered twice daily and the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is administered once a day at night.

83. The claims of 26-82, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, are formulated into an oral unit dose dosage form.

84. The claim of 79, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, are administered concurrently.

85. The claim of 79, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, are administered simulataneously.

86. The claim of 79, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, are administered sequentially.

87. The claims of 26-45, wherein the subject is a female.

88. The claims of 48-86, wherein the subject is a female.

89. The claims of 26-37, wherein the subject is a male.

90. The claims of 46-86, wherein the subject is a male.

91. The use of bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof in the manufacture of a medicament together with instructions for its use in the treatment of a sexual disorder in a subject.

92. The claim of 91, wherein the sexual disorder is hypoactive sexual desire disorder (HSDD).

93. The claims of 91-92, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a sustained release oral dosage form.

94. The claims of 91-92, wherein the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in an extended release oral dosage form.

95. The claims of 91-92, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a sustained release oral dosage form and the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in an extended release oral dosage form.

96. The claims of 91-95, wherein the subject is a female.

97. The claims of 91-95, wherein the subject is a male.

98. The use of bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof in the manufacture of a medicament together with instructions for its use in the prevention of a sexual disorder in a subject.

99. The claim of 98, wherein the sexual disorder is hypoactive sexual desire disorder (HSDD).

100. The claims of 98-99, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a sustained release oral dosage form.

101. The claims of 98-99, wherein the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in an extended release oral dosage form.

102. The claims of 98-99, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a sustained release oral dosage

form and the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in an extended release oral dosage form.

103. The claims of 98-102, wherein the subject is a female.

104. The claims of 98-102, wherein the subject is a male.

105. The use of bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof in the manufacture of a medicament together with instructions for its use to modulate hypoactive sexual desire disorder (HSDD) in a subject.

106. The claim of 105, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a sustained release oral dosage form.

107. The claim of 105, wherein the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in an extended release oral dosage form.

108. The claim of 105, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in a sustained release oral dosage form and the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, is in an extended release oral dosage form.

109. The claim of 105-108 wherein the subject is a female.

110. The claims of 105-108, wherein the subject is a male.

111. The claim of 38, wherein the female sexual dysfunction is described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-V).

112. The claims of 26-47, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, are in a ratio of 9 to 1.

113. The claims of 26-47, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, are in a ratio of 8 to 1.

114. The claims of 26-47, wherein the bupropion, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, and the trazodone, or any salt, solvate, hydrate, isomer, enantiomer, diastereomer, racemate or metabolite thereof, are in a ratio of 7 to 1.